Table 4. Clinical trials evaluating dendritomes as an immunotherapeutic intervention in cancer patients.*.
| Indications | Trials | Phase | Status | Notes | Ref. |
|---|---|---|---|---|---|
| AML |
1 |
II |
Recruiting |
Combined with CT-011 or GM-CSF |
NCT01096602 |
| B-cell lymphoma Multiple myeloma |
1 |
I-II |
Unknown |
As single agent |
NCT00937183 |
| Breast cancer |
1 |
I-II |
Recruiting |
Alone or combined with IL-12 |
NCT00622401 |
| Melanoma |
2 |
I-II |
Unknown |
As single agent |
NCT00626860 |
| II |
Active, not recruiting |
NCT01042366 |
|||
| Non-Hodgkin lymphoma |
1 |
n.a. |
Recruiting |
Combined with cryotherapy and a pneumococcal polyvalent vaccine |
NCT01239875 |
| Renal cell carcinoma |
2 |
I-II |
Completed |
As single agent |
NCT00625755 |
| II |
Recruiting |
Combined with CT-011 |
NCT01441765 |
||
| Reproductive tract cancer | 1 | II | Active, not recruiting |
Combined with GM-CSF ± imiquimod | NCT00799110 |
AML, acute myeloid leukemia; GM-CSF, granulocyte macrophage colony-stimulating factor; IL-12, interleukin-12; n.a., not available. *Started after January, 1st 2008.